Pre-clinical biotech company ImmunoScape received $6 million from Amgen Ventures, the corporate venture capital arm of US-based biopharma firm Amgen, last week. The investment is part of a $14 million financing announced in September.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
